Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000467046 | SCV000549413 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2022-01-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 1331 of the BRCA1 protein (p.Gln1331Arg). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 21318380). ClinVar contains an entry for this variant (Variation ID: 409366). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
University of Washington Department of Laboratory Medicine, |
RCV003157522 | SCV003849199 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Ambry Genetics | RCV003157522 | SCV005547451 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-09-20 | criteria provided, single submitter | clinical testing | The p.Q1331R variant (also known as c.3992A>G), located in coding exon 9 of the BRCA1 gene, results from an A to G substitution at nucleotide position 3992. The glutamine at codon 1331 is replaced by arginine, an amino acid with highly similar properties. This alteration has been reported in an unaffected individual with a family history of breast cancer (Hansen TV et al. Fam Cancer, 2011 Jun;10:207-12). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |